tbuckley/cabot-search huggingface dataset:
Phase I/II study of mogamulizumab, an anti-CCR4 antibody targeting regulatory T cells in advanced cancer patients.
Authors: George Plitas, Kenmin Wu, Jeremie Carlson, Nicholas Cimaglia, Monica Morrow, Alexander Y. Rudensky, Jedd D. Wolchok
Journal: Journal of Clinical Oncology (2016)

TPS3098 Background: Regulatory T cells (Treg) are a subset of CD4 T cells that preserve immune homeostasis by the establishment and maintenance of peripheral tolerance. This suppressive function however, limits anti-tumor immune responses and represents a critical obstacle to immunotherapy. Multiple preclinical models have demonstrated effective anti-tumor immunity by targeting Treg cells. Human tumor-infiltrating Treg cells express high levels of the chemokine receptor CCR4. Based on these findings we developed a Phase I/II clinical trial investigating the activity of Mogamulizumab, a fully humanized, IgG1, monoclonal, depleting, anti-CCR4 antibody in patients with advanced solid organ malignancies. Methods: Eligible patients include those with histologically confirmed solid organ malignancies, adequate performance status, and organ function who are not eligible for, have declined, or have failed standard treatment. Up to 24 patients will be enrolled in the phase I study and the dose of Mogamulizumab will be escalated according to a standard 3+3 design. Mogamulizumab will be administered weekly for the first month and then every two weeks for up to a year or until progressive disease or unacceptable toxicity. The primary study end points are safety/tolerability and identification of the maximum tolerated dose (MTD), which will be taken forward in a phase II study. Secondary objectives include evaluating clinical activity as assessed by tumor response (RECIST v1.1 and Immune-related Response Criteria), progression-free survival, and overall survival. Exploratory objectives include determining the extent of tumor and peripheral blood Treg cell depletion as well as the correlative immunologic changes. Tumor biopsies will be available both pre-treatment and during treatment. The first two dose escalation cohorts have been accrued. The phase II study will continue to evaluate the safety and preliminary efficacy of mogamulizumab at the MTD in 48 patients with triple negative breast cancer, gastric adenocarcinoma, and non-small cell lung cancer. Clinical trial information: NCT02281409. Clinical trial information: NCT02281409.
Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension
Authors: Dudley J Pennell, John B Porter, Antonio Piga, Yongrong Lai, Amal El-Beshlawy, Khawla Belhoul, Mohsen Elalfy, Akif Yesilipek, Yurdanur Kilinç, Antje Wegener, Dany Habr, Junwu Shen, Yesim Aydinok
Journal: Blood (2013)
Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials.
Authors: Carsten Denkert, Karsten Weber, Kristin Krappmann, Jens Bodo Huober, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kummel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani, Volkmar Mueller, Annette Staebler, Keyur Mehta, Gunter Von Minckwitz, Ralf Kronenwett, Sibylle Loibl
Journal: Journal of Clinical Oncology (2016)

522 Background: Gene expression assays are well-established prognostic tools for planning of adjuvant therapy in luminal breast cancer (BC). In the neoadjuvant setting, pCR is not an optimal prognostic factor in luminal BC, and additional parameters are needed. In this study, we evaluated the gene expression test EndoPredict (EP) performed on residual tumor specimen after NACT for predicting prognosis in patients (pts) with ER+/HER2- BC who did not achieve a pCR and compared its prognostic power with the CPS-EG score. Methods: 428 post-NACT FFPE samples of HR+/HER2- BC from the GeparTrio and -Quattro trials were evaluated for mRNA expression of BIRC5, RBBP8, UBE2C, IL6ST, AZGP1, DHCR7, MGP and STC2 by qRT-PCR. The molecular EP and the clinico-molecular EPclin scores were calculated using predefined algorithms and cutoffs. CPS-EG was determined as previously published (Marmé et al. Eur J Cancer). Uni- and multivariate Cox proportional hazard models were used. Results: 175 (41%) of the 428 pts were EPclin low-risk. The continuous EPclin score was significantly associated with poor DFS (HR 2.16 per score unit; 95% CI 1.86-2.51, p < 0.0001). Using predefined diagnostic cutpoints, EPclin high-risk pts had a significantly reduced DFS (HR 4.22; 2.57-6.92; p < 0.0001) and OS (HR 3.66; 2.00-6.69; p < 0.0001). Increased CPS-EG was also significantly linked to poor DFS (HR 2.95; 2.02-4.33; p < 0.0001) and OS (HR 3.70; 2.29-5.99; p < 0.0001). In a bivariate analysis, in contrast to CPS-EG the EPclin score remained significantly prognostic for reduced DFS (HR 2.09, 1.73-2.53, p < 0.0001) and OS (HR 2.16, 1.72-2.72, p < 0.0001). Conclusions: In this prospectively planned biomarker study we show that the information in the hybrid clinico-molecular EPclin score is also prognostic for DFS and OS after NACT and is superior to the clinical CPS-EG score. This approach can be used to assess prognosis after NACT in the luminal non-pCR patient population, and select patients for post-NACT therapies, e.g. treatment with CDK4/6 inhibitors. An additional prospective validation is planned in the ongoing Penelope trial.
The Supply of Rural Physicians
Authors: Robert C. Morrow
Journal: JAMA (1993)

To the Editor.  —Rosenblatt et al 1 conclude, as a result of correlational analysis, that the organization, location, and mission of US medical schools are closely related to the production of rural practitioners. These conclusions are strengthened and refined by factor analysis of the matrix of intercorrelations between 10 selected variables that they provide in Table 4 (p 1563).  Three underlying factors account for 66% of the variance of this correlation matrix. Factor analysis is appropriate for this data set since the variables are intercorrelated (Kaiser-Meyer-Olkin measure of sampling adequacy = 0.69; Bartlett test of sphericity, P   The factor loadings (of.6000 or greater) of the study
Le projet Salm-gene : une collaboration européenne pour les empreintes génétiques des salmonelloses liées à l'alimentation
Authors: T M Peters, C Maguire, E J Threlfall, I. S.T. Fisher, O N Gill, A J Gatto
Journal: Eurosurveillance (2003)

Le projet Salm-gene a mene en Europe une evaluation externe d'assurance qualite de la technique de PFGE pour identifier le serotype, voire le lysotype des salmonelles. Une serie de 16 souches de S. Enteritidis a ete envoyee a 10 laboratoires nationaux de reference pour les salmonelles. En suivant un protocole harmonise, les profils de PFGE obtenus etaient comparables entre les centres. Dans la plupart des cas, le taux de similitude etait de 90%, depassant souvent les 95%. Ceci suggere que les analyses en PFGE sont reproductibles, et qu'elles sont des outils precieux d'investigation, en association avec les donnees epidemiologiques.
Modeling behavioral adaptations
Authors: Colin W. Clark
Journal: Behavioral and Brain Sciences (1991)

Abstract Optimization models have often been useful in attempting to understand the adaptive significance of behavioral traits. Originally such models were applied to isolated aspects of behavior, such as foraging, mating, or parental behavior. In reality, organisms live in complex, ever-changing environments, and are simultaneously concerned with many behavioral choices and their consequences. This target article describes a dynamic modeling technique that can be used to analyze behavior in a unified way. The technique has been widely used in behavioral studies of insects, fish, birds, mammals, and other organisms. The models use biologically meaningful parameters and variables, and lead to testable predictions. Limitations arise because nature's complexity always exceeds our modeling capacity.
Diffuse Large B-Cell Lymphoma (DLBCL) Tumor Cells Reprogram Lymphatic Fibroblasts into Cancer-Associated Fibroblasts (CAFs) That Contribute to Tumor Microenvironment (TME)-Driven Immune Privilege
Authors: Benedetta Apollonio, Nicole S. Nicholas, Lesley-Ann Sutton, Jon Salisbury, Piers E. Patten, Shireen Kassam, Stephen Devereux, Rose Marie Amini, Richard Rosenquist, Alan G. Ramsay
Journal: Blood (2015)
New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition
Authors: M. Cem Ar, Emrah Yucesan, Firat Yalniz, Ozden Hatirnaz Ng, Ayse Salihoglu, Selin Berk, Ahmet Emre Eskazan, Seniz Ongoren, Zafer Baslar, Ugur Ozbek, Teoman Soysal, Yildiz Aydin, Muge Sayitoglu
Journal: Blood (2015)
Correlates of skin-related quality of life (QoL) in those with multiple keratinocyte carcinomas (KCs): A cross-sectional study
Authors: Julia A. Siegel, Mary-Margaret Chren, Martin A. Weinstock, Martin A. Weinstock, Kimberly Marcolivio, Martin A. Weinstock, Suephy C. Chen, Robert P. Dellavalle, Erin M. Warshaw, John J. DiGiovanna, Ryan Ferguson, Robert A. Lew, Robert J. Ringer, Jean Yoon, Ciaran S. Phibbs, Ken Kraemer, Daniel Hogan, David Eilers, Susan M. Swetter, Suephy C. Chen, Sharon Jacob, Laura Romero, Erin M. Warshaw, George P. Stricklin, Robert P. Dellavalle, Nellie Konnikov, Victoria Werth, Navjeet Sidhu-Malik, Jonette E. Keri, James W. Swan, Kristin Nord, Brian Pollack, Stephen Kempiak, Whitney High, Nicole Fett, Russell P. Hall, Javier Alonso-Llamazares, Georgette Rodriguez, Lorine Sisler, Mary O'Sullivan, Sonya Wilson, Madhuri Agrawal, Debra Bartenfeld, Keith Nicalo, Deb Johnson, Patricia Parks, Barbara Bidek, Nancy Boyd, Barbara Watson, Dianne Wolfe, Mark Zacheis, Joyce Okawa, Mary Ann Iannacchione, Jalima Quintero, Subbarayudu Cuddapah, Karen Muller, Vanessa Lichon, Todd Anhalt, Vista Khosravi, Zakia Rahman, Leslie Lawley, Roberta McCoy, Neal Foman, Andrea Bershow, John Zic, Jami Miller, H. Alan Arbuckle, Linnea Hemphill, Mayumi Fujita, David Norris, Preethi Ramaswamy, Jennifer Nevas, Caroline H. Rao, Allen J. Gifford, Kelly A. Asher, Adela Rambi G. Cardones, Angela F. Richardson, Carmen Adams Patrick, Louis Fiore, Ryan Ferguson, Soe Soe Thwin, Robert A. Lew, Clara E. Kebabian, Jennifer Pavao, Mike Sather, Carol Fye, Robert J. Ringer, David Hunt, Leslie Robinson-Bostom, Gladys Telang, Caroline Wilkel, Harley A. Haynes, Maurice Alan Brookhart, Eliot N. Mostow, Thomas Rector
Journal: Journal of the American Academy of Dermatology (2016)
Lower Rates of Heart Failure and Death in Acute Coronary Syndromes—Reply
Authors: Keith A. A. Fox
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection
Authors: Jeffrey S. Wefel, Kyle R. Noll, Ganesh Rao, Daniel P. Cahill
Journal: Neuro-Oncology (2016)

Patients with malignant gliomas present with variation in neurocognitive function (NCF) not attributable to lesion size or location alone. A potential contributor is the rate at which tumors grow, or "lesion momentum." Isocitrate dehydrogenase 1 wild type (IDH1-WT) are more proliferative and aggressive than IDH1-mutant (IDH1-M) tumors. We hypothesized that patients with IDH1-WT would exhibit worse NCF than patients with IDH1-M tumors. Comprehensive NCF testing was completed in 119 patients with malignant glioma prior to surgical resection. IDH1 status was determined with immunohistochemistry and sequencing. Rates of impairment and mean test performances were compared by IDH1. NCF impairment was significantly more frequent in patients with IDH1-WT tumors in memory, processing speed, visuoconstruction, language, executive functioning, and manual dexterity. Mean performances of patients with IDH1-WT were also significantly lower than those with IDH1-M tumors on measures of learning and memory, processing speed, language, executive functioning, and dexterity. Lesion volume was not statistically different between IDH1-WT and IDH1-M tumors. Tumor and lesion volume on T1-weighted and fluid attenuated inversion recovery MRI were significantly associated with most NCF tests in patients with IDH1-WT, but only significantly associated with a single measure in patients with IDH1-M tumors. Patients with IDH1-WT show reduced NCF compared with those with IDH1-M malignant gliomas. Lesion volume is inversely associated with NCF for patients with IDH1-WT, but not IDH1-M tumors. These findings are consistent with the hypothesis that patients with IDH1-WT tumors present with more severe NCF impairment due to greater lesion momentum, which may impede compensatory neuroplasticity and cerebral reorganization.
Patient-Physician Communication: Respect for Culture, Religion, and Autonomy-Reply
Authors: Lawrence O. Gostin
Journal: JAMA (1996)

In Reply.  —Scholars in health law and bioethics focus intensely on the right of patients to make autonomous decisions about their medical treatment. This is thought to require full disclosure of truthful information to assist the patient in the process of informed consent. Legal and ethical approval of the principle of autonomy has been so consistent that full and truthful information disclosure is broadly accepted as the standard of practice in medical care. Patients cannot genuinely arrive at meaningful choices about their health care unless they are apprised of all material benefits, adverse effects, and risks, including an informed assessment of their prognosis with and without treatment. Patients are faced with decisions that intimately and powerfully affect their lives. Medicine demonstrates its respect for persons by illuminating patients' decisions with information, not by making decisions for them.  The fact that autonomous decision making usually demands full information does not mean
Mutational Studies Using Next Generation Sequencing in High Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Patients Treated with Azacitidine (High risk MDS 2009 protocol from CETLAM Group)
Authors: Marta Cabezon, Joan Bargay, Blanca Xicoy, Laura Palomo, Sílvia Marcé, Ramón Guàrdia, Salut Brunet, Carmen Pedro, Mar Tormo, Vera Ademà, Victor Marco, Lourdes Escoda, Llorenç Font, Elena Rámila, Josep Maria Martí, David Valcarcel, Josep Borras, Evarist Feliu, Fuensanta Millá, Lurdes Zamora
Journal: Blood (2015)
Are Absolute Monocyte Count and The Lymphocyte-Monocyte Ratio (LMR) Valid Prognostic Factors In Classical Hodgkin Lymphoma? An Evaluation Based On Data From 1079 Patients
Authors: Stefano Sacchi, Alessia Bari, Tamar Tadmor, Luigi Marcheselli, Samantha Pozzi, Eliana Valentina Liardo, Angela Ferrari, Caterina Stelitano, Paolo G Gobbi, Luca Baldini, Daniele Vallisa, Emilio Iannitto, Aaron Polliack, Massimo Federico
Journal: Blood (2013)
The Pentose Phosphate Pathway Regulates the Circadian Clock
Authors: Guillaume Rey, Utham K. Valekunja, Kevin A. Feeney, Lisa Wulund, Nikolay B. Milev, Alessandra Stangherlin, Laura Ansel-Bollepalli, Vidya Velagapudi, John S. O’Neill, Akhilesh B. Reddy
Journal: Cell Metabolism (2016)

The circadian clock is a ubiquitous timekeeping system that organizes the behavior and physiology of organisms over the day and night. Current models rely on transcriptional networks that coordinate circadian gene expression of thousands of transcripts. However, recent studies have uncovered phylogenetically conserved redox rhythms that can occur independently of transcriptional cycles. Here we identify the pentose phosphate pathway (PPP), a critical source of the redox cofactor NADPH, as an important regulator of redox and transcriptional oscillations. Our results show that genetic and pharmacological inhibition of the PPP prolongs the period of circadian rhythms in human cells, mouse tissues, and fruit flies. These metabolic manipulations also cause a remodeling of circadian gene expression programs that involves the circadian transcription factors BMAL1 and CLOCK, and the redox-sensitive transcription factor NRF2. Thus, the PPP regulates circadian rhythms via NADPH metabolism, suggesting a pivotal role for NADPH availability in circadian timekeeping.
Early-Life Exposure to Perfluoroalkyl Substances and Childhood Metabolic Function
Authors: Abby F. Fleisch, Sheryl L. Rifas-Shiman, Ana M. Mora, Antonia M. Calafat, Xiaoyun Ye, Heike Luttmann-Gibson, Matthew W. Gillman, Emily Oken, Sharon K. Sagiv
Journal: Environmental Health Perspectives (2016)

Background:Perfluoroalkyl substances (PFASs) are synthetic chemicals that may persist in the environment and in humans. There is a possible association between early-life PFAS exposure and metabolic dysfunction in later life, but data are limited.Methods:We studied 665 mother–child pairs in Project Viva, a Boston, Massachusetts-area cohort recruited 1999–2002. We quantified concentrations of PFASs [perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), perfluorononanoate (PFNA), perfluorohexane sulfonate (PFHxS), and perfluorodecanoate (PFDeA)] in maternal plasma collected at the first prenatal visit (median, 9.6 weeks gestation) and in child plasma from the mid-childhood research visit (median, 7.7 years). We assessed leptin, adiponectin, and homeostatic model assessment of insulin resistance (HOMA-IR) in mid-childhood. We fit covariate-adjusted linear regression models and conducted stratified analyses by child sex.Results:Children with higher PFAS concentrations had lower HOMA-IR [e.g., –10.1% (95% CI: –17.3, –2.3) per interquartile range increment in PFOA]. This inverse association between child PFAS and HOMA-IR was more pronounced in females [e.g., PFOA: –15.6% (95% CI: –25.4, –4.6) vs. –6.1% (95% CI: –16.2, 5.2) for males]. Child PFAS plasma concentrations were not associated with leptin or adiponectin. Prenatal PFAS plasma concentrations were not associated with leptin, adiponectin, or HOMA-IR in offspring.Conclusions:We found no evidence for an adverse effect of early-life PFAS exposure on metabolic function in mid-childhood. In fact, children with higher PFAS concentrations had lower insulin resistance.Citation:Fleisch AF, Rifas-Shiman SL, Mora AM, Calafat AM, Ye X, Luttmann-Gibson H, Gillman MW, Oken E, Sagiv SK. 2017. Early-life exposure to perfluoroalkyl substances and childhood metabolic function. Environ Health Perspect 125:481–487; http://dx.doi.org/10.1289/EHP303
P0688 : Preclinical characterisation of MIV-802, a novel uridine nucleotide HCV NS5B polymerase inhibitor, for treatment of hepatitis C virus infection
Authors: A. Lindqvist, H. Kylefjord, H. Wähling, S. Juric, S. Torssell, G. Kalayanov, L. Vrang, E. Hoberg, C. Gustafsson, A. Eneroth, E. Lindström, K. Wikström, P. Targett-Adams, P. Pinho, R. Bethell, Å. Rosenquist
Journal: Journal of Hepatology (2015)
Brazil sees sharp rise in chikungunya cases
Authors: Cláudia Collucci
Journal: BMJ (2016)

Brazil recorded 170 000 cases of chikungunya virus disease in the first half of this year—10 times the number seen in the same period in 2015, health ministry records show. Deaths have also risen from six in 2015 to 38 so far this year.1

Brazil now accounts for 94% of confirmed cases of the disease in the Americas, according to the Pan American Health Organization.2

Chikungunya virus is transmitted by the Aedes aegypti mosquito, the same mosquito that carries the Zika virus—which has been declared a public health emergency in …
Aspirin and Cancer Risk
Authors: Samer Al Hadidi
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Transrectal MR-guided laser focal therapy of recurrent prostate cancer in a patient post-proton therapy: A case study.
Authors: Bernadette Marie Greenwood, Stuart May, John Francis Feller
Journal: Journal of Clinical Oncology (2016)

e298 Background: Prostate cancer is commonly managed with radical prostatectomy (RP) or radiation therapy (RT). 20-40% of men undergoing RP experience biochemical recurrence (BCR) before 10 years. 30-50% or those receiving RT experience BCR. Treatment options for these men are limited and include: salvage radiation, close surveillance, androgen deprivation therapy (ADT), or participation in a clinical trial. Our IRB-approved study evaluated the use of transrectally delivered, MR-guided laser focal therapy with real-time MR thermometry for the treatment of recurrent prostate cancer. Methods: 63 y.o. patient treated September, 2014 with MR-guided laser focal salvage therapy for locally recurrent prostate cancer, Gleason score 4+5 involving the transition zone far anteriorly at the base level measuring 1.4 x 1.1 x 1.3 cm. The patient was originally diagnosed with Gleason score 4+3 adenocarcinoma of the prostate by MR ultrasound fusion biopsy in 2012 and subsequently underwent treatment with proton beam radiation therapy. Results: MR-guided biopsy of the prostate August, 2014 confirmed the presence of locally recurrent PCa. Before MR-guided laser focal therapy, the biochemical recurrence was documented with an elevated serum PSA equal to 5.7. The 3- and 6-month post laser focal therapy serum PSA levels were 0.5. It reached a nadir of 0.3 at one year following the laser ablation. Patient had negative 6-month follow-up MR-guided biopsy of treatment region and remains on active surveillance Conclusions: Following proton beam radiation therapy, transrectal MR-guided laser focal therapy achieved oncologic control at 12 months post-treatment. Clinical trial information: 02243033.
CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation
Authors: Cor H. J. Lamers, Rebecca Wijers, Cornelis A. M. van Bergen, Judith A. E. Somers, Eric Braakman, Jan Willem Gratama, Reno Debets, J. H. Frederik Falkenburg, Jan J. Cornelissen
Journal: Blood (2016)